Role of α-Adrenergic Receptors in the Effect of the β-Adrenergic Receptor Ligands, CGP 12177, Bupranolol, and SR 59230A, on the Contraction of Rat Intrapulmonary Artery

Journal of Pharmacology and Experimental Therapeutics

Volumn 309, Issue 1, 2004, Pages 137-145

  Leblais, Véronique ^a   Pourageaud, Fabrice ^a   Ivorra, M Dolores ^c   Guibert, Christelle ^b   Marthan, Roger ^b   Muller, Bernard ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b Lab de Physiol Cell Respiratoire   (France)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 ETHYLPHENOXY) 3 (1,2,3,4 TETRAHYDRO 1 NAPHTHYLAMINO) 2 PROPANOL OXALATE; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID METHYL ESTER; 5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUPRANOLOL; PARTIAL AGONIST; PHENOXYBENZAMINE; PHENTOLAMINE; PHENYLEPHRINE; PRAZOSIN; PROSTAGLANDIN F2 ALPHA; TRITIUM;

ANIMAL TISSUE; ARTERY CONSTRICTION; ARTERY DILATATION; ARTICLE; BLOOD VESSEL TONE; CALCIUM CELL LEVEL; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; RAT; RECEPTOR INTRINSIC ACTIVITY;

EID: 1642309257     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.061192     Document Type: Article

References (41)

1. Berlan M, Galitzky J, Bousquet-Melou A, Lafontan M, and Montastruc JL (1994) Beta-3 adrenoceptor-mediated increase in cutaneous blood flow in the dog. J Pharmacol Exp Ther 268:1444-1451.
2. Bhattacharya B and Roberts RE (2003) Enhancement of alpha(2)-adrenoceptor-mediated vasoconstriction by the thromboxane-mimetic U46619 in the porcine isolated ear artery: role of the ERK-MAP kinase signal transduction cascade. Br J Pharmacol 139:156-162.
3. Blin N, Camoin L, Maigret B, and Strosberg AD (1993) Structural and conformational features determining selective signal transduction in the beta 3-adrenergic receptor. Mol Pharmacol 44:1094-1104.
4. Boer C, van der Linden PJ, Scheffer GJ, Westerhof N, de Lange JJ, and Sipkema P (2002) RhoA/Rho kinase and nitric oxide modulate the agonist-induced pulmonary artery diameter response time. Am J Physiol Heart Circ Physiol 282:H990-H998.
5. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
6. Brahmadevara N, Shaw AM, and MacDonald A (2003) Evidence against beta 3-adrenoceptors or low affinity state of beta 1-adrenoceptors mediating relaxation in rat isolated aorta. Br J Pharmacol 138:99-106.
7. Brawley L, Shaw AM, and MacDonald A (2000) Beta 1-, beta 2- and atypical beta-adrenoceptor-mediated relaxation in rat isolated aorta. Br J Pharmacol 129:637-644.
8. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
9. Choppin A and O'Connor SE (1995) Presence of vasoconstrictor 5HT1-like receptors revealed by precontraction of rabbit isolated mesenteric artery. Br J Pharmacol 114:309-314.
10. Dumas M, Dumas JP, Bardou M, Rochette L, Advenier C, and Giudicelli JF (1998) Influence of beta-adrenoceptor agonists on the pulmonary circulation. Effects of a beta3-adrenoceptor antagonist, SR 59230A. Eur J Pharmacol 348:223-228.
11. Fabi F, Argiolas L, Ruvolo G, and del Basso P (1998) Neuropeptide Y-induced potentiation of noradrenergic vasoconstriction in the human saphenous vein: involvement of endothelium generated thromboxane. Br J Pharmacol 124:101-110.
12. Feve B, Emorine LJ, Lasnier F, Blin N, Baude B, Nahmias C, Strosberg AD, and Pairault J (1991) Atypical beta-adrenergic receptor in 3T3-F442A adipocytes. Pharmacological and molecular relationship with the human beta 3-adrenergic receptor. J Biol Chem 266:20329-20336.
13. Granneman JG (2001) The putative beta4-adrenergic receptor is a novel state of the beta1-adrenergic receptor. Am J Physiol Endocrinol Metab 280:E199-E202.
14. Granneman JG, Lahners KN, and Chaudhry A (1991) Molecular cloning and expression of the rat beta 3-adrenergic receptor. Mol Pharmacol 40:895-899.
15. Henrion D and Laher I (1994) Insulin potentiates norepinephrine-induced vascular tone by activation of protein kinase C and tyrosine kinase. Can J Physiol Pharmacol 72:849-854.
16. Horinouchi T and Koike K (2001) Agonistic activity of SR59230A at atypical beta-adrenoceptors in guinea pig gastric fundus and duodenum. Eur J Pharmacol 416:165-168.
17. Kaumann AJ, Preitner F, Sarsero D, Molenaar P, Revelli JP, and Giacobino JP (1998) (-)-CGP 12177 causes cardiostimulation and binds to cardiac putative beta 4-adrenoceptors in both wild-type and beta 3-adrenoceptor knockout mice. Mol Pharmacol 53:670-675.
18. Kenakin T (1993) Pharmacologic Analysis of Drug-Receptor Interaction. Raven Press, Ltd., New York.
19. Konkar AA, Zhai Y, and Granneman JG (2000a) Beta1-adrenergic receptors mediate beta3-adrenergic-independent effects of CGP 12177 in brown adipose tissue. Mol Pharmacol 57:252-258.
20. Konkar AA, Zhu Z, and Granneman JG (2000b) Aryloxypropanolamine and catecholamine ligand interactions with the beta(1)-adrenergic receptor: evidence for interaction with distinct conformations of beta(1)-adrenergic receptors. J Pharmacol Exp Ther 294:923-932.
21. Kozlowska H, Szymska U, Schlicker E, and Malinowska B (2003) Atypical (beta1-adrenoceptors, different from (beta)3-adrenoceptors and probably from the low-affinity state of (beta)1-adrenoceptors, relax the rat isolated mesenteric artery. Br J Pharmacol 140:3-12.
22. Leach RM, Twort CH, Cameron IR, and Ward JP (1992) A comparison of the pharmacological and mechanical properties in vitro of large and small pulmonary arteries of the rat. Clin Sci (Lond) 82:55-62.
23. Leblais V, Pourageaud F, Marthan R, and Muller B (2003) Evidence for contribution of alpha-adrenoceptors in the effects of CGP 12177 in rat pulmonary arteries (Abstract). Fundam Clin Pharmacol 17:227-269.
24. Lowe MD, Lynham JA, Grace AA, and Kaumann AJ (2002) Comparison of the affinity of beta-blockers for two states of the beta 1-adrenoceptor in ferret ventricular myocardium. Br J Pharmacol 135:451-461.
25. MacDonald A, McLean M, MacAulay L, and Shaw AM (1999) Effects of propranolol and L-NAME on beta-adrenoceptor-mediated relaxation in rat carotid artery. J Auton Pharmacol 19:145-149.
26. Madrero Y, Elorriaga M, Martinez S, Noguera MA, Cassels BK, D'Ocon P, and Ivorra MD, (1996) A possible structural determinant of selectivity of boldine and derivatives for the alpha 1A-adrenoceptor subtype. Br J Pharmacol 119:1563-1568.
27. Molenaar P (2003) The 'state' of beta-adrenoceptors. Br J Pharmacol 140:1-2.
28. Movahedi H and Purdy RE (1997) Pharmacological characterization of the "silent" 5-hydroxytryptamine1B-like receptors of rabbit ear artery. J Pharmacol Exp Ther 283:653-660.
29. Nanoff C, Freissmuth M, and Schutz W (1987) The role of a low beta 1-adrenoceptor selectivity of [3H]CGP-12177 for resolving subtype-selectivity of competitive ligands. Naunyn-Schmiedeberg's Arch Pharmacol 336:519-525.
30. Nisoli E, Tonello C, Landi M, and Carruba MO (1996) Functional studies of the first selective beta 3-adrenergic receptor antagonist SR 59230A in rat brown adipocytes. Mol Pharmacol 49:7-14.
31. Oriowo MA (1994) Atypical beta-adrenoceptors in the rat isolated common carotid artery. Br J Pharmacol 113:699-702.
32. Preitner F, Muzzin P, Revelli JP, Seydoux J, Galitzky J, Berlan M, Lafontan M, and Giacobino JP (1998) Metabolic response to various beta-adrenoceptor agonists in beta3-adrenoceptor knockout mice: evidence for a new beta-adrenergic receptor in brown adipose tissue. Br J Pharmacol 124:1684-1688.
33. Rautureau Y, Toumaniantz G, Serpillon S, Jourdon P, Trochu JN, and Gauthier C (2002) Beta 3-adrenoceptor in rat aorta: molecular and biochemical characterization and signalling pathway. Br J Pharmacol 137:153-161.
34. Shafiei M and Mahmoudian M (1999) Atypical beta-adrenoceptors of rat thoracic aorta. Gen Pharmacol 32:557-562.
35. Shen YT, Cervoni P, Claus T, and Vatner SF (1996) Differences in beta 3-adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs. J Pharmacol Exp Ther 278:1435-1443.
36. Staehelin M, Simons P, Jaeggi K, and Wigger N (1983) CGP-12177. A hydrophilic beta-adrenergic receptor radioligand reveals high affinity binding of agonists to intact cells. J Biol Chem 258:3496-3502.
37. Strange JW, Wharton J, Phillips PG, and Wilkins MR (2002) Recent insights into the pathogenesis and therapeutics of pulmonary hypertension. Clin Sci (Lond) 102:253-268.
38. Strosberg AD (1997) Structure and function of the beta 3-adrenergic receptor. Annu Rev Pharmacol Toxicol 37:421-450.
39. Tamaoki J, Tagaya E, Isono K, and Nagai A (1998) Atypical adrenoceptor-mediated relaxation of canine pulmonary artery through a cAMP-dependent pathway. Biochem Biophys Res Commun 248:722-727.
40. Trochu JN, Leblais V, Rautureau Y, Beverelli F, Le Marec H, Berdeaux A, and Gauthier C (1999) Beta 3-adrenoceptor stimulation induces vasorelaxation mediated essentially by endothelium-derived nitric oxide in rat thoracic aorta. Br J Pharmacol 128:69-76.
41. Yan M, Sun J, Bird PI, Liu DL, Grigg M, and Lim YL (2001) Alpha1A- and alpha1B-adrenoceptors are the major subtypes in human saphenous vein. Life Sci 68:1191-1198.